Acadia pharmaceuticals inc(ACAD.US AI Earnings Summary)
ACAD AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
- Stock Price Reaction: Strong revenue growth and an upward revision of the full-year guidance for the flagship drug DAYBUE drove the stock price higher. On November 4, 2026, ET, ACAD shares closed up 4.38% at $21.47. Since the earnings report was released after-hours, the late-session and latest price action fluctuated between the $20.69 to $21.47 range.
- Market Expectations: ACAD's 2026 Q3 Non-GAAP total revenue reached $342M, exceeding the Wall Street consensus estimate ($332M) cited in reports accompanying this transcript by approximately 3.0%. The primary drivers were net sales of the flagship rare disease drug DAYBUE reaching $140M (up 39% YoY) and net sales of the Parkinson’s disease psychosis drug NUPLAZID reaching $202M (up 12% YoY), with both showing strong growth in patient demand and shipment volumes.
- Performance Against Guidance: Core product performance exceeded expectations this quarter, leading the company to adjust its full-year revenue and expense outlook accordingly. DAYBUE net sales of $140M (up 39% YoY) prompted management to raise the lower end of the full-year guidance for DAYBUE; NUPLAZID net sales of $202M aligned with the expected trajectory and narrowed the full-year guidance range. R&D expenses were well-managed at approximately $76M, coming in below the annualized guidance budget pace.
- In One Sentence: Strong demand for the dual flagship drugs DAYBUE and NUPLAZID pushed revenue past consensus, as the company raised full-year DAYBUE guidance and reaffirmed long-term growth ambitions, with the market responding via a 4.38% stock price increase to $21.47 during the reporting day's trading session.
Quarterly Highlights
DAYBUE hit a record high, becoming the strongest growth engine this quarter and exceeding market consensus. Total adjusted revenue for the quarter was $342M, approximately 3.0% higher than the market consensus of $332M cited in external reports, primarily driven by DAYBUE.
DAYBUE achieved a record single-quarter sales performance since launch: Net sales for DAYBUE reached $140M this quarter, a 39% increase YoY, with almost all growth driven by volume. The continued penetration of the DAYBUE STIX powder oral solution formulation is the core driver; by the end of the quarter, over 50% of U.S. DAYBUE patients were using the STIX formulation, with usage levels comparable to or slightly higher than the historical liquid formulation.
DAYBUE STIX opens a new growth dimension through "patient restarts": Chief Commercial Officer Tom Garner noted that previously discontinued patients represent a new growth opportunity brought by STIX. Currently, over 80% of discontinued patients have not yet tried STIX, representing significant re-engagement potential. Community physicians contributed nearly 80% of referrals in Q3, and community-side penetration is currently around 30%, leaving substantial room for growth.
DAYBUE U.S. patent protection extended to 2041, significantly lengthening exclusivity: A notice of allowance was received from the USPTO this quarter for a patent covering the weight-based dosing regimen shared by DAYBUE oral solution and STIX. Protection is expected to extend to March 2041 including pediatric exclusivity, nearly five years longer than the original expiration date, providing a stronger legal foundation for long-term commercial investment.
DAYBUE approved in the EU and launched commercially in Germany first: Approval was granted by the European Commission this quarter, making it the first and only approved treatment for the neurobehavioral symptoms of Rett syndrome in the EU. It was officially launched commercially in Germany in early October, with a positive initial response and patients already transitioning from the compassionate use program to commercial drug use.
NUPLAZID volume growth drives steady performance, hitting a brand record: Adjusted net sales for NUPLAZID reached $202M this quarter, up 12% YoY, with 11 percentage points coming from volume growth. New brand prescription (NBRx) growth continued to outperform the same period last year. Direct-to-consumer advertising reached over 1.3 million eligible Parkinson's patients by September, with approximately one in ten following up with a doctor visit, resulting in over 1,500 people starting NUPLAZID.
R&D expenses decreased 13% YoY, with cost control better than internal expectations: R&D expenses were $76.3M this quarter, down from $87.8M in the same period last year, mainly due to reduced spending on studies completed in 2025, partially offset by increased spending on remlifanserin and ACP-211. Full-year R&D expense guidance was revised downward to $325M–$340M, lower than the $355M–$380M range provided last quarter.
Cash position reached $976M, providing ample financial flexibility: Cash and investment balances reached $976M at quarter-end. CFO Mark Schneyer stated this is a true strategic asset that can support pipeline investment, business development, and commercial execution without the need for external financing.
Full-year DAYBUE guidance raised as management reaffirms long-term 2028 targets: Full-year DAYBUE net sales guidance was raised to $505M–$520M, up from the $480M–$510M provided last quarter. Management also reaffirmed the long-term goal of $700M in DAYBUE sales by 2028 and stated the new patent provides further confidence for continued investment through 2041.